Jon Faiz Kayyem - 03 Jun 2026 Form 4/A - Amendment Insider Report for Inhibrx Biosciences, Inc. (INBX)

Reporting relationship: Director
Issuer ticker: INBX
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 18 Sep 2026, 16:20:29 UTC
Original report date: 04 Jun 2026
Prior SEC filing: 06 Jan 2026
Next SEC filing: 08 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem

Key filing fact

Jon Faiz Kayyem filed Form 4/A - Amendment for Inhibrx Biosciences, Inc. (INBX) on 18 Sep 2026.

Key facts

This page summarizes Jon Faiz Kayyem's Form 4/A - Amendment filing for Inhibrx Biosciences, Inc. (INBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Sep 2026, 16:20.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001366268 Primary reporting owner

Kayyem Jon Faiz

Relationship: Director
Address: C/O INHIBRX BIOSCIENCES, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA
Signature: /s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Signature date: 18 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $95.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

SEC remarks

This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error.